Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.
Analysts have set a twelve-month consensus price target of $2.27 for the company and are expecting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also given Zomedica Pharmaceuticals Corp (NYSEAMERICAN) an industry rank of 74 out of 256 based on the ratings given to related companies.
Separately, HC Wainwright reissued a “buy” rating on shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in a report on Wednesday, June 5th.
NYSE ZOM traded down $0.01 during trading hours on Friday, hitting $0.26. 6,381 shares of the stock were exchanged, compared to its average volume of 123,688. The stock has a market capitalization of $26.48 million, a P/E ratio of -1.48 and a beta of 0.80. Zomedica Pharmaceuticals Corp has a 12-month low of $0.20 and a 12-month high of $2.98.
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last posted its quarterly earnings results on Friday, May 10th. The company reported ($0.12) earnings per share (EPS) for the quarter. On average, equities research analysts predict that Zomedica Pharmaceuticals Corp will post -0.26 earnings per share for the current year.
Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Company Profile
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.
Featured Story: How to Use a Moving Average for Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.